Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Eszter Gáspár"'
Publikováno v:
Biomedicines, Vol 12, Iss 9, p 2117 (2024)
Background/Objectives: Lupus nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE). The aim of our retrospective cohort study was to compare the clinical characteristics, therapy, survival, causes of deat
Externí odkaz:
https://doaj.org/article/778abe747daa487cb2ac02263de81a2d
Autor:
Gabriella Gálffy, Éva Morócz, Réka Korompay, Réka Hécz, Réka Bujdosó, Rita Puskás, Tímea Lovas, Eszter Gáspár, Kamel Yahya, Péter Király, Zoltán Lohinai
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adj
Externí odkaz:
https://doaj.org/article/e143b06eb3c247d1b271fdb7f6e965e5
Publikováno v:
Lupus Science and Medicine, Vol 11, Iss Suppl 1 (2024)
Externí odkaz:
https://doaj.org/article/bd5780e5248c4d1e80c3aaa32d66017a
Autor:
Nikolett Nagy, Bernadett Bói, Gábor Papp, Edit Fiák, Eszter Gáspár-Kiss, Bianka Perge, Nikolett Farmasi, Tünde Tarr
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 530 (2024)
In systemic lupus erythematosus (SLE), cardiovascular complications are among the leading causes of death. Cardiovascular risk in SLE is even higher in the presence of antiphospholipid antibodies or secondary antiphospholipid syndrome (APS). The aim
Externí odkaz:
https://doaj.org/article/00cde99548a04c7f97bf28a8722da32e
Publikováno v:
Biomedicines, Vol 11, Iss 4, p 1218 (2023)
Systemic lupus erythematosus (SLE) is often associated with antiphospholipid syndrome (APS), which potentially results in a more severe disease course and reduced life expectancy. Since the therapeutic guidelines have been refined in the last 15 year
Externí odkaz:
https://doaj.org/article/74bd3490b06b4b62bc928faefc0b0a68